Michael Ostland

Michael Ostland is the VP of Development for Europe at Denali Therapeutics. Michael has over 10 years of experience in the pharmaceutical industry, specifically in development and commercialization of compounds for the treatment of various diseases.

Ostland began their career at Roche in 2012 as the Head of Biostatistics. In this role, they led a team of 220 Analytical Scientists who provided expert input to drug development projects across a portfolio of diseases. In 2016, they became the Lifecycle Leader and was responsible for the development and launch of Evrysdi, a treatment for Spinal Muscular Atrophy (SMA).

Ostland has been with Denali Therapeutics since March of 2022 and has been instrumental in the company's success in Europe. Under their leadership, Denali has developed and launched several new treatments for various diseases.

Michael Ostland's educational career includes a Doctor of Philosophy (Ph.D.) in Statistics from the University of California, Berkeley and a Bachelor of Arts (B.A.) in Mathematics from UC San Diego.

They are on a team with Wei Dong - VP, Drug Safety, Steve Krognes - Board Member, and Kirk Henne - VP, Translational Pharmacology and Bioanalysis. Their manager is Ryan Watts, CEO.